Canada markets close in 6 hours 23 minutes

Novozymes A/S (NVZMY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
51.28+1.23 (+2.46%)
As of 03:58PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close50.05
Open50.40
BidN/A x N/A
AskN/A x N/A
Day's Range50.40 - 51.51
52 Week Range48.11 - 83.31
Volume22,594
Avg. Volume23,326
Market Cap13.84B
Beta (5Y Monthly)0.35
PE Ratio (TTM)35.37
EPS (TTM)1.45
Earnings DateN/A
Forward Dividend & Yield0.82 (1.63%)
Ex-Dividend DateMar 17, 2022
1y Target Est62.32
  • GlobeNewswire

    Novozymes delivers strong half year results and narrows full-year outlook upwards

    Novozymes delivered solid earnings and double-digit organic sales growth in both the first half and in the second quarter. Despite the volatile market environment, the company narrows its full-year organic sales outlook upwards from 4-8% to now 6-8% and raises EBIT-margin expectations from 25-26% to now 26-27%. COPENHAGEN, Denmark – August 11, 2022. Novozymes delivers 10% organic sales growth and an EBIT-margin of 26% in the first half of the year, with 18% organic sales growth in DKK. Good mome

  • GlobeNewswire

    Novozymes plan to further increase prices across the portfolio in response to the significant and persistent hike in incoming cost

    Novozymes has experienced unprecedented cost-inflation on raw materials, energy, and logistics. To recover these headwinds, substantial price increases will be implemented. COPENHAGEN, Denmark – 15 July 2022. Novozymes has been able to partially shield its customers from a large part of the global challenges, securing business continuity and high price stability relative to other suppliers. However, Novozymes will further substantially increase prices at a level at least in line with the current

  • Zacks

    AXTA vs. NVZMY: Which Stock Is the Better Value Option?

    AXTA vs. NVZMY: Which Stock Is the Better Value Option?